CVM
AMEXCEL-SCI
$2.13
-0.61 (-22.26%)
2026-10-07 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$29.2M
P/E Ratio
N/A
52W Low
52W High
$0.89
$10.39
Volume
661K
Analyst Rating
Hold
Target: $21
9 Analyst Ratings
Strong Buy
0
Buy
0
Hold
9
Sell
0
Price Target Range
Low: $12
Avg: $21
High: $25
About CEL-SCI
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...
Website
cel-sci.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$25.4M | -$17.1M |
| 2024 | N/A | N/A% | -$26.9M | -$18.7M |
| 2023 | N/A | N/A% | -$32.4M | -$22.5M |
| 2022 | N/A | N/A% | -$36.7M | -$17.6M |
| 2021 | N/A | N/A% | -$36.4M | -$9.7M |
| 2026 Q2 | N/A | N/A% | -$5.7M | -$4.0M |
| 2026 Q1 | N/A | N/A% | -$5.5M | -$4.0M |
| 2025 Q4 | N/A | N/A% | -$5.5M | -$4.0M |
| 2025 Q3 | N/A | N/A% | -$6.1M | -$4.7M |
| 2025 Q2 | N/A | N/A% | -$5.7M | -$3.9M |
| 2025 Q1 | N/A | N/A% | -$6.6M | -$4.4M |
| 2024 Q4 | $6.0M | -115.8% | -$7.1M | -$4.1M |
| 2024 Q3 | N/A | N/A% | -$6.1M | -$18.7M |